Adenosine A2A receptor (A2AR) neurons represent a distinct population of striatal medium spiny neurons (MSNs) that co-express the adenosine A2A receptor. These neurons are primarily located in the indirect pathway of the basal ganglia and play a crucial role in motor control, reward processing, and neuroprotection[1][2]. A2A receptors are G protein-coupled receptors that couple to Gs/olf proteins, leading to increased intracellular cAMP levels and excitatory signaling.
| Property | Value |
|---|---|
| Category | Striatal Medium Spiny Neurons |
| Location | Striatum (indirect pathway) |
| Neurotransmitter | GABA |
| Receptor | Adenosine A2A Receptor |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000197 | sensory receptor cell | Medium |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000197 | sensory receptor cell |
The A2A receptor is a G protein-coupled receptor (GPCR) belonging to the adenosine receptor family (A1, A2A, A2B, A3). Structurally, it consists of seven transmembrane helices connected by three extracellular and three intracellular loops. The orthosteric binding site is located within the transmembrane domain, where endogenous adenosine binds with moderate affinity (Kd ~ 10-20 μM in the presence of GTP)[3].
Key molecular features include:
The receptor exhibits unique pharmacological properties compared to other adenosine receptor subtypes. It has the highest affinity for adenosine among all subtypes and demonstrates marked species differences in ligand binding kinetics. In human striatum, A2A receptor density is approximately 10-15 pmol/mg protein, representing one of the highest GPCR densities in the brain[1:1].
A2A receptor activity is tightly regulated through multiple mechanisms:
A2A-expressing MSNs are characterized by specific neurochemical markers:
A critical feature of A2A-expressing neurons is the formation of A2A-D2 receptor heteromers. These GPCR complexes represent the basis for the well-documented antagonistic interaction between adenosine and dopamine signaling in the striatum[4][5]:
A2A receptor neurons are integral to the indirect pathway of the basal ganglia motor circuit[6][3:1]:
The indirect pathway functions as a "braking system" for movement:
A2A receptor signaling in indirect pathway MSNs opposes D2 receptor signaling. While D2 activation inhibits MSNs and reduces motor output, A2A activation excites MSNs and promotes motor suppression. This antagonism forms the basis for Parkinson's disease therapy.
A2A neurons modulate motor behavior through multiple mechanisms[7]:
In Parkinson's disease, loss of dopaminergic input leads to excessive indirect pathway activity, causing bradykinesia and rigidity. A2A antagonists restore motor function by blocking A2A-mediated excitation of indirect pathway MSNs.
A2A receptors modulate dopaminergic signaling in reward circuits[8][9]:
A2A receptors play complex roles in neuroprotection and neuroinflammation[10][11][12]:
A2A MSNs have distinctive electrophysiological properties that differ from D1-expressing direct pathway MSNs:
| Property | Value | Notes |
|---|---|---|
| Resting membrane potential | -70 to -80 mV | Similar to D1 MSNs |
| Input resistance | ~100 MΩ | Higher than D1 MSNs |
| Action potential duration | ~1.5 ms | Slightly longer than D1 |
| Firing pattern | Low-frequency tonic | Irregular, pause-field-pause |
| Up state duration | 2-4 seconds | Longer than D1 MSNs |
Synaptic properties:
A2A receptors are major therapeutic targets in PD[7:1][15][16][17]:
A2A receptors are dysregulated in HD[20]:
| Compound | Status | Indication |
|---|---|---|
| Istradefylline | Approved (Japan, US) | PD adjunct |
| Preladenant | Phase II complete | PD |
| ST1535 | Phase I/II | PD |
| Lu AE58054 | Phase II | PD dementia |
Schiffmann et al. Adenosine A2A receptors in basal ganglia (2007). 2007. ↩︎ ↩︎
Cunha et al. Adenosine receptors as neuromodulators (2008). 2008. ↩︎
Halldner et al. Adenosine as a neuromodulator in basal ganglia (2009). 2009. ↩︎ ↩︎
Fuxe et al. A2A-D2 receptor heteromers (2005). 2005. ↩︎ ↩︎
Orru et al. A2A-D2 receptor heteromer pharmacology (2011). 2011. ↩︎ ↩︎
Pinna et al. Adenosine A2A receptor antagonists for Parkinson's disease (2020). 2020. ↩︎ ↩︎
Ferré et al. A2A-D2 receptor interactions in reward (2010). 2010. ↩︎
Chen et al. A2A receptors in synaptic plasticity (2019). 2019. ↩︎
Schwarz et al. A2A receptor and neuroinflammation (2017). 2017. ↩︎
Gomez et al. Astrocyte A2A receptors in neurodegeneration (2021). 2021. ↩︎
Boison et al. Adenosine and neurodegeneration (2012). 2012. ↩︎ ↩︎
Naskar et al. A2A receptors in blood-brain barrier (2019). 2019. ↩︎
Hu et al. A2A receptor and mitochondrial function (2015). 2015. ↩︎
Mendoza et al. A2A receptor blockade and alpha-synuclein (2019). 2019. ↩︎ ↩︎
Yu et al. Caffeine and neuroprotection in PD (2017). 2017. ↩︎
Park et al. Caffeine consumption and PD risk meta-analysis (2021). 2021. ↩︎
Saurah et al. A2A antagonists and levodopa-induced dyskinesia (2022). 2022. ↩︎
Brichta et al. A2A receptor gene variants and PD risk (2022). 2022. ↩︎
Swanson et al. A2A receptors in Huntington's disease (2022). 2022. ↩︎
Ries et al. A2A receptors in sleep-wake regulation (2020). 2020. ↩︎